Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer ...
SPRING, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc. in Spring, Texas, announces collaborative publication of data from preclinical studies with scientists at The University of Texas MD Anderson Cancer Center demonstrating effectiveness …